Clinical trial

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NCT03794544

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-03-08

PhasePHASE2

Study timeline

Study start (actual)2019-03-08Date precision: day

Registry last updated2022-02-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Resectableunresolved

Early-stageunresolved

NSCLCunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

OleclumabCOMBINATION_PRODUCT

MonalizumabCOMBINATION_PRODUCT

DanvatirsenCOMBINATION_PRODUCT

Sponsors & collaborators

MedImmune LLClead sponsor

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 BaltimoreMaryland, United States1 NashvilleTennessee, United States1 BarcelonaSpain1 MontrealQuebec, Canada1 La JollaCalifornia, United States1 ToulouseFrance1 MarseilleFrance1 BuffaloNew York, United States1 FairfaxVirginia, United States1 Fort MyersFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03794544 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.